Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy?

被引：0
|
作者：
Hideaki Yamakawa
Tamiko Takemura
Tae Iwasawa
Yumie Yamanaka
Satoshi Ikeda
Akimasa Sekine
Hideya Kitamura
Tomohisa Baba
Shinichiro Iso
Koji Okudela
Kazuyoshi Kuwano
Takashi Ogura
机构：
[1] Kanagawa Cardiovascular and Respiratory Center,Department of Respiratory Medicine
[2] Japanese Red Cross Medical Center,Department of Pathology
[3] Kanagawa Cardiovascular and Respiratory Center,Department of Radiology
[4] Yokohama Rousai Hospital for Labour Welfare Corporation,Department of Radiology
[5] Yokohama City University Graduate School of Medicine,Department of Pathobiology
[6] Tokyo Jikei University Hospital,Department of Respiratory Medicine
来源：
BMC Pulmonary Medicine | / 18卷
关键词：
Systemic sclerosis; Emphysematous change; Vasculopathy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy?
    Yamakawa, Hideaki
    Takemura, Tamiko
    Iwasawa, Tae
    Yamanaka, Yumie
    Ikeda, Satoshi
    Sekine, Akimasa
    Kitamura, Hideya
    Baba, Tomohisa
    Iso, Shinichiro
    Okudela, Koji
    Kuwano, Kazuyoshi
    Ogura, Takashi
    [J]. BMC PULMONARY MEDICINE, 2018, 18
  • [2] Update on scleroderma-associated interstitial lung disease
    Fan, Ming-Hui
    Feghali-Bostwick, Carol A.
    Silver, Richard M.
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2014, 26 (06) : 630 - 636
  • [3] Effect Of Mycophenolate Mofetil On Scleroderma-Associated Interstitial Lung Disease
    Baqir, M.
    Makol, A.
    Osborn, T. G.
    Bartholmai, B.
    Ryu, J.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [4] A New Era in the Treatment of Scleroderma-associated Interstitial Lung Disease?
    Launay, David
    [J]. JOURNAL OF RHEUMATOLOGY, 2016, 43 (09) : 1619 - 1621
  • [5] SCLERODERMA-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
    Silver, R.
    [J]. RHEUMATOLOGY, 2012, 51 : I12 - I12
  • [6] Safety and Tolerability of Thrombin Inhibition in Scleroderma-Associated Interstitial Lung Disease
    Silver, R. M.
    Wilson, D. A.
    Akter, T.
    Atanelishvili, I.
    Huggins, J. T.
    Kajdasz, K.
    Highland, K. B.
    Nietert, P. J.
    Bogatkevich, G. S.
    [J]. ACR OPEN RHEUMATOLOGY, 2019, 1 (07) : 403 - 411
  • [7] Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab
    McGonagle, D.
    Tan, A. L.
    Madden, J.
    Rawstron, A. C.
    Rehman, A.
    Emery, P.
    Thomas, S.
    [J]. RHEUMATOLOGY, 2008, 47 (04) : 552 - 553
  • [8] Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease
    Zamora, Ana C.
    Wolters, Paul J.
    Collard, Harold R.
    Connolly, M. Kari
    Elicker, Brett M.
    Webb, W. Richard
    King, Talmadge E., Jr.
    Golden, Jeffrey A.
    [J]. RESPIRATORY MEDICINE, 2008, 102 (01) : 150 - 155
  • [9] Clinical features of scleroderma sine scleroderma-associated progressive interstitial lung disease.
    Fischer, A
    Cosgrove, GP
    Collard, HR
    Feghali-Bostwick, CA
    Loucks, J
    West, SG
    Meehan, RT
    Brown, KK
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S589 - S589
  • [10] Cardiovascular comorbidity in Danish patients with scleroderma-associated interstitial lung disease
    Madsen, Gitte Anna
    Hyldgaard, Charlotte
    Bendstrup, Elisabeth
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2017, 50
12345